5Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ ATS criteria for severe CAP using meta-analysis and observational data[J]. Eur Respir J, 2014, 43(3) : 842-851. DOI: 10. 1183/ 09031936. 00089513.
6Cao B, Zhao C J, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China [ J ]. Clin Infect Dis, 2010, 51 (2) : 189-194. DOI: 10. 1086/653535.
7Liu Y, Chen M, Zhao T, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population[ J]. BMC Infect Dis, 2009, 9: 31. DOI: 10. 1186/1471-2334-9-31.
8Von Baum H, Wehe T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa : Diagnosis, incidence and predictors [ J ]. Eur Respir J, 2010, 35 (3): 598-605. DOI: 10. 1183/09031936. 00091809.
9Einhorn AE, Neuhauser MM, Bearden DT, et al. Extended- spectrum beta-laetamases: frequency, risk factors, and outcomes [ J]. Pharmacotherapy, 2002, 22(1 ): 14-20.